Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!

MDxHealth SA, announced today that it has granted a non-exclusive worldwide license for its patented methylation-specific PCR (MSP) technology to QIAGEN for use in its new CE-marked QIAsure assay to determine cervical cancer risk.

Under the terms of the agreement, QIAGEN has licensed the use of MDxHealth's MSP technology, a proprietary DNA-methylation specific PCR methodology, for the development and commercialization of its new diagnostic test which differentiates patients' risk of developing cervical cancer. MDxHealth will receive a signing fee plus royalties from future test sales utilizing this technology.

QIAGEN reported that the QIAsure test is a highly complementary addition to its leading human papilloma virus (HPV) franchise. Women screening positive for HPV, or with abnormal cells identified by cytology, are at increased risk of developing cervical cancer. The QIAsure test is the next logical step to assess this risk. More information about the QIAsure product launch can be found at: QIAGEN launches QIAsure Methylation Test to determine cervical cancer risk.

"We are pleased that our Methylation technology can further support QIAGEN's efforts to improve women's health," stated Dr. Jan Groen, CEO of MDxHealth. "Cervical cancer is the fourth most common cancer in women worldwide, with an estimated 528,000 new cases diagnosed and 266,000 deaths each year, so clearly this is an important test."

About QIAGEN

QIAGEN N.V. (qiagen.com), a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide.

About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.